| 7th Feb 2024 11:30 am |
EQS |
Transaction Update |
| 29th Jan 2024 12:15 pm |
EQS |
Results of First General Meeting |
| 24th Jan 2024 5:30 pm |
EQS |
Holding(s) in Company |
| 24th Jan 2024 5:30 pm |
EQS |
Holding(s) in Company |
| 23rd Jan 2024 7:00 am |
EQS |
Update on the Scheme and Publication of Notice of Second General Meeting |
| 22nd Jan 2024 7:00 am |
EQS |
Update on the Scheme and Resignation of Directors |
| 19th Jan 2024 7:01 am |
EQS |
Financial update on Harpoon Therapeutics acquisition by Merck (MSD) |
| 19th Jan 2024 7:00 am |
EQS |
Unaudited NAV for December 2023 |
| 8th Jan 2024 5:15 pm |
EQS |
Portfolio company Harpoon Therapeutics to be acquired by Merck (MSD) |
| 5th Jan 2024 7:00 am |
EQS |
Publication of Circular and RTW Bio Prospectus |
| 4th Jan 2024 5:30 pm |
EQS |
Holding(s) in Company |
| 22nd Dec 2023 11:00 am |
EQS |
Update regarding timing of Proposed Scheme of Reconstruction |
| 13th Dec 2023 7:00 am |
EQS |
Unaudited NAV for November 2023 |
| 8th Dec 2023 7:00 am |
EQS |
Portfolio Company Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial |
| 13th Nov 2023 4:00 pm |
EQS |
Correction: Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock |
| 10th Nov 2023 8:00 am |
EQS |
Portfolio Company Aura Biosciences Announces Closing of $99 million Public Offering of Common Stock |
| 10th Nov 2023 7:00 am |
EQS |
PDMR Notification & Director Shareholding |
| 8th Nov 2023 7:05 am |
EQS |
Unaudited NAV for October 2023 |
| 3rd Nov 2023 4:30 pm |
EQS |
PDMR Notification & Director Shareholding |
| 2nd Nov 2023 6:20 pm |
EQS |
PDMR Notification & Director Shareholding |
| 1st Nov 2023 4:30 pm |
EQS |
Portfolio Company Sorriso Pharmaceuticals Announces First Subject Dosed in Phase 1/1b Clinical Trial of SOR102 |
| 1st Nov 2023 7:06 am |
RNS |
RTW Biotech to acquire Arix Bioscience's assets |
| 24th Oct 2023 7:00 am |
EQS |
Portfolio company Harpoon Therapeutics announces up to $150 million private placement |
| 6th Oct 2023 7:00 am |
EQS |
Unaudited NAV for September 2023 |
| 27th Sep 2023 7:01 am |
EQS |
Interim Results for the Six Months Ended 30 June 2023 |
| 27th Sep 2023 7:00 am |
EQS |
Board Change |
| 14th Sep 2023 7:01 am |
EQS |
Notice of Results and Investor Presentation |
| 14th Sep 2023 7:00 am |
EQS |
Unaudited NAV for August 2023 |
| 7th Aug 2023 7:00 am |
EQS |
Unaudited NAV for July 2023 |
| 17th Jul 2023 3:00 pm |
EQS |
Holding(s) in Company |
| 13th Jul 2023 7:01 am |
EQS |
Arix Announces Strategic Review |
| 13th Jul 2023 7:00 am |
EQS |
Unaudited NAV for June 2023 |
| 23rd Jun 2023 2:04 pm |
EQS |
Portfolio company Disc Medicine raises $157.8 million in public offering |
| 9th Jun 2023 2:53 pm |
EQS |
Portfolio company Disc Medicine presents positive initial data from Phase 2 BEACON trial at EHA |
| 9th Jun 2023 7:00 am |
EQS |
Unaudited NAV for May 2023 |
| 31st May 2023 11:51 am |
RNS |
Director/PDMR Shareholding |
| 24th May 2023 7:00 am |
EQS |
Correction: Result of Annual General Meeting |
| 23rd May 2023 4:30 pm |
EQS |
Result of Annual General Meeting |
| 16th May 2023 4:36 pm |
EQS |
Portfolio company Ensoma announces closing of Series B Extension |
| 12th May 2023 7:00 am |
EQS |
Unaudited NAV for April 2023 |
